Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Ariel Focus Fund Ariel Investments, LLC | “Dentsply Sirona is undergoing a strategic turnaround to address structural pressures in its capital equipment division. The steady characteristics of the dental industry and management's operational reset should enable margin expansion and long-term value realization.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Ariel Fund John W. Rogers, Jr. | “Also during the quarter, we added Dentsply Sirona (XRAY), a leading global dental manufacturing company, to the portfolio. Since acquiring Sirona Dental in 2016, the company has faced challenges, particularly in its core capital equipment business, which has come under pressure from lower-cost technology alternatives. Despite these headwinds, we view the dental market favorably given its attractive dynamics: steady growth, lower reimbursement risk, and higher out-of-pocket spending compared to other healthcare segments. Management is executing a strategic reset focused on innovative product development and portfolio expansion, operational efficiencies, emerging market growth and bolt-on acquisitions to strengthen competitive positioning. With these initiatives underway, we believe XRAY is well-positioned to capitalize on secular growth trends, improve margins and drive long-term shareholder value. BSD Analysis: Dentsply Sirona is rebuilding credibility after years of operational missteps and complexity. Dental demand is resilient, driven by recurring procedures rather than discretionary spending. Simplification efforts are improving execution and cost structure. Product innovation remains relevant, but salesforce effectiveness is key. Investors price in permanent dysfunction. Stabilization alone would rerate the stock meaningfully. Dental practices don't switch suppliers lightly. If execution normalizes, earnings power looks understated. This is a fix-the-business story, not a broken market.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Heartland Value Fund The Heartland Investment Team | “Last quarter, we discussed how management at Dentsply Sirona, Inc. (XRAY), one of the world's leading suppliers of dental equipment and supplies, had been laying the groundwork for a turnaround for more than two years. Those efforts had yet to be reflected in the stock price. In the third quarter, CEO Simon Campion stepped down after three years at the helm and was replaced by Daniel Scavilla. Under Campion, XRAY focused on SKU rationalization and other cost initiatives but failed to keep up with its peers in terms of top-line growth. CEO Scavilla has a record of sales success at Globus Medical Inc. and Johnson & Johnson. We are encouraged by his initial strategies to arm the sales force better to go to market with the company's existing portfolio and near-term goals to improve margins and free cash flows. Dentsply was among the Fund's worst performers for the quarter, however trading at 6.7X estimated earnings, its valuation seems extremely discounted. Thus we will remain patient and sit tight with the position believing that the upside potential far outweighs the downside risk. However, our patience has a limit, and we will closely monitor XRAY's progress. BSD Analysis: Leadership change plus a renewed sales focus could catalyze a multi-year margin and FCF recovery on top of prior SKU rationalization. At ~6–7x EPS, the stock embeds low expectations; execution could drive a sharp re-rating. Monitor organic growth reacceleration, gross margin lift, and working capital discipline. Downside contained by valuation; thesis rests on operating turnaround.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Heartland Value Fund The Heartland Investment Team | “Dentsply Sirona, Inc. (XRAY) is another small cap that happens to be an industry leader. The result of the merger of Dentsply International and Sirona Dental Systems nearly a decade ago, XRAY is a $13.3 billion company that is one of the world's biggest suppliers of dental equipment and supplies, including consumables, lab products, and orthodontics and implants. For more than two years, management has been laying the groundwork for a turnaround. Those efforts have yet to be reflected in the stock price, as the company continues to course correct from poor decisions made by prior leadership. XRAY's efforts have been hampered by sluggish global economic growth, as the company's largest geography, the European Union, has been stalled in a dental recession for the past three years. XRAY's U.S. implant business, meanwhile, also continues to struggle, though there are some early signs of improved performance ahead. For example, Dentsply's Q1 results — including its Orthodontic and Implant Solutions segment — beat analyst expectations for revenues and earnings. The company isn't out of the woods, but this was a significant step forward for a stock that has been pricing in worst-case scenarios in recent months. We continue to support the CEO's pragmatic, customer-focused approach to improving market share in key areas and implementing self-help strategies to improve XRAY's operational and strategic efficiencies. In addition to meeting its commitments on earnings, margin, and free cash flow improvements, management has been accelerating new product launches and finding success in centralizing storage and access of patient data on its DS Core cloud-based platform. Yet the stock remains discounted, trading at just 7X estimated Enterprise Value/EBITDA. BSD Analysis: Dentsply Sirona is a deeply discounted industrial compounder in the dental technology market, poised for a major EBITDA inflection as its aggressive operational clean-up and restructuring complete. The core thesis is a return to sustainable, high-single-digit growth driven by the successful integration of clear aligner and digital dentistry technologies. The company's moat lies in its end-to-end digital workflow, which locks dentists into a unified system covering everything from imaging (Axeos) to restoration (Primescan/SureSmile). The stock is trading at a significant discount due to the historical noise of accounting probes and executive turmoil; however, the new management team has surgically executed a turnaround, achieving $50 million in annualized cost savings. This cost discipline is setting the stage for substantial operating margin expansion and accelerated Free Cash Flow (FCF) generation. The valuation arbitrage is compelling: investors are buying the leader in digital dentistry at a trough multiple, ahead of the inevitable re-rating as the new operating model delivers consistent, predictable profitability.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Heartland Value Fund The Heartland Investment Team | “Despite a sharp selloff triggered by voluntary product suspension and subsequent regulatory reviews, Dentsply Sirona presents a highly compelling turnaround opportunity. The manager has added to the position on weakness, confident in new leadership's ability to drive a major $300 million self-help cost-saving program. The stock remains heavily discounted, trading at rock-bottom earnings and cash flow multiples.” | BULL | Q4 2024 Dec 31, 2024 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
